You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Emerging technologies included biosensors, host response tests using different types of biomarkers, and new ways to make and develop antigen, antibody, and PCR tests.
The iQ Group Global is integrating the Wyss Institute's technology with its own organic thin-film biosensor platform for SARS-CoV-2 serology testing.
Wyss Institute said iQ Group Global will integrate its affinity-based technology with a biosensor platform that includes organic thin-film transistors to enhance electrical signals.
The Assurance Testing Alliance will handle the logistics and operations required to connect labs with groups in need of regular SARS-CoV-2 testing.
Semi-quantitative SARS-CoV-2 serology tests enable users to measure levels of neutralizing antibodies, but tests need to be more comparable across manufacturers, Siemens said.
The company licensed nasopharyngeal swab and toehold switch molecular detection technologies from the Wyss Institute to develop SARS-CoV-2 diagnostics.
Some lab experts say that Abbott's test is open to multiple variables, which could lead to improper use and incorrect test results.
The Harvard University spinout uses a combination of proprietary probes, nanoarrays, and convection PCR to target a broad set of molecular biomarkers.
In a preliminary study, the group reported high accuracy for the detection of breast cancer within an hour by combining a fluorescence flow cytometer with fine-needle biopsies.
A pilot study will be conducted to examine the integration of the Biosensor platform with an assay system to detect IgM and IgG antibodies.